OCX - Oncocyte Corp

2.84
0.070   2.465%

Share volume: 38,206
Last Updated: 04-07-2025
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.01%

PREVIOUS CLOSE
CHG
CHG%
$2.77
0.07
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 23%
Liquidity 25%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.74%
1 Month
-31.89%
3 Months
27.35%
6 Months
-6.58%
1 Year
-2.07%
2 Year
-59.45%
Key data
Stock price
$2.84
P/E Ratio 
0.00
DAY RANGE
$2.63 - $2.91
EPS 
-$3.91
52 WEEK RANGE
$1.92 - $4.75
52 WEEK CHANGE
-$2.41
MARKET CAP 
40.068 M
YIELD 
N/A
SHARES OUTSTANDING 
13.368 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.37
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$67,932
AVERAGE 30 VOLUME 
$92,088
Company detail
CEO: Joshua Riggs
Region: US
Website: oncocyte.com
Employees: 120
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

OncoCyte Corporation researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services.

Recent news
loading